Vimseltinib elicited an ORR of 40% vs 0% of matching placebo in patients with tenosynovial giant cell tumor in the phase 3 MOTION trial.
Approval Alert | Vimseltinib in Tenosynovial Giant Cell Tumors
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab Combo Elicits No Significant Benefit in Ovarian Cancer
2
How Will Gastrointestinal Cancer Standards of Care Change? An ESMO Recap
3
Glofitamab/Polatuzumab Vedotin Exhibits Response Durability in R/R LBCL
4
Forming CUTNETs: A Joint Venture Between Surgery and Oncology in NETs
5
